Hidden in Plain Sight: Earlier Detection of HFpEF and Cardiac Amyloidosis to Improve AF Ablation and LAAC Outcomes – Powered by Ultromics

Patients arrive in the electrophysiology lab carrying diagnoses we can see and conditions we often cannot. Heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis (CA) frequently hide behind a presentation of atrial fibrillation, yet both reshape the atrial substrate, the thromboembolic profile, and the durability of the rhythm-control strategies we offer. This roundtable asks a deceptively simple question: if we identified these conditions earlier, before the ablation or the appendage closure, would we make better procedural decisions and achieve better outcomes for our patients?
Using Ultromics’ FDA-cleared EchoGo® platform, which detects HFpEF and cardiac amyloidosis from a single, routinely acquired echocardiographic view, the panel will work through how earlier phenotyping could refine candidate selection, pre-procedure patient management, periprocedural planning, and anticoagulation strategy for AF ablation and LAAC. The discussion is designed to be candid and clinically grounded: where the evidence supports a change in practice, where it does not yet, and what an EP-ready screening workflow would actually look like.